


CLAIMS

1. A sulfonamide compound of general formula (Ia),



5

(Ia),

wherein

10 R¹ represents a -NR⁸R⁹ radical or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, which may contain at least one heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

15 R², R³, R⁵, R⁶ and R⁷, identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl or an optionally at least mono-substituted heteroaryl radical,

20 R⁴ is hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

R⁸ and R⁹, identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

5 with the proviso that R⁸ and R⁹ are not hydrogen at the same time, and if one of them, R⁸ or R⁹, is a saturated or unsaturated, linear or branched, optionally at least mono-substituted C₁-C₄ aliphatic radical, the other one is a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical with at least five carbon atoms, or

10 R⁸ and R⁹ together with bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may 15 optionally contain at least one heteroatom as a ring member,

20 A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

and





25 n is 0, 1, 2, 3 or 4;

30 optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof.


2. A compound according to claim 1, characterized in that R¹ represents a -NR⁸R⁹ radical or a saturated or unsaturated optionally at least mono-substituted 5- or 6-membered cycloaliphatic radical, which may optionally contain at least one heteroatom as a ring member and which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring, which may optionally contain at least one heteroatom as a ring member, whereby the rings of the ring system are 5- or 6-membered,

10

preferably R¹ represents a -NR⁸R⁹ radical or a radical chosen from the group consisting of



and



wherein, if present, the dotted line represents an optional chemical bond, and R¹⁰ represents hydrogen, a linear or branched C₁-C₆ alkyl radical or a benzyl radical, preferably hydrogen or a C₁-C₂ alkyl radical.

15

20

3. A compound according to claim 1 or 2, characterized in that R², R³, R⁵, R⁶ and R⁷, identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C₁-C₆ alkyl radical, a linear or branched, optionally at least mono-substituted C₂-C₆ alkenyl radical, or a linear or branched, optionally at least mono-substituted C₂-C₆ alkynyl radical,

preferably R², R³, R⁵, R⁶ and R⁷, identical or different, each represent hydrogen or a linear or branched , optionally at least mono-substituted C₁-C₆ alkyl radical,

5

more preferably R², R³, R⁵, R⁶ and R⁷ each represent hydrogen.

4. A compound according to one or more of claims 1 to 3, characterized in that R⁴ represents hydrogen, a linear or branched, optionally at least 10 mono-substituted C₁-C₆ alkyl radical, a linear or branched, optionally at least mono-substituted C₂-C₆ alkenyl radical, a linear or branched, optionally at least mono-substituted C₂-C₆ alkynyl radical

15 preferably R⁴ represents hydrogen or a linear or branched , optionally at least mono-substituted C₁-C₆ alkyl radical,

more preferably R⁴ represents hydrogen or a C₁-C₂ alkyl radical.

5. A compound according to one or more of claims 1 to 4, characterized in 20 that R⁸ and R⁹, identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C₁-C₁₀ alkyl radical, a linear or branched, optionally at least mono-substituted C₂-C₁₀ alkenyl radical, a linear or branched, optionally at least mono-substituted C₂-C₁₀ alkynyl radical, or

25 R⁸ and R⁹ together with bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted 5- or 6-membered heterocyclic ring which may contain at least one additional heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic 30 cycloaliphatic ring, which may optionally contain at least one heteroatom as a ring member, whereby the rings of the ring system are 5- 6- or 7-






membered.

6. A compound according to claim 5, characterized in that R⁸ and R⁹, identical or different, each represent hydrogen or a linear or branched C₁-C₁₀ alkyl radical,


5

or

- 10 R⁸ and R⁹ together with the bridging nitrogen atom form a radical chosen from the group consisting of



and



wherein R¹¹, if present, represents hydrogen, a linear or branched C₁-C₆ alkyl radical or a benzyl radical, preferably hydrogen, or a C₁-C₂ alkyl radical.

15

7. A compound according to one or more of claims 1 to 6, characterized in that A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered, which may be bonded via an optionally at least mono-substituted C₁-C₆ alkylene group, an optionally at least mono-substituted C₂-C₆ alkenylene group or an optionally at least mono-substituted C₂-C₆ alkynylene group and/or wherein the ring(s) may contain at least one heteroatom as a ring member,


20

25

preferably A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom,

5

or a radical chosen from the group consisting of



10

wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, linear or branched C₁-C₆ alkyl, linear or branched C₁-C₆ alkoxy, linear or branched C₁-C₆ alkylthio, a trifluoromethyl radical, a cyano radical and a -NR¹²R¹³ radical,

15

wherein R¹² and R¹³, identical or different, each represent hydrogen or linear or branched C₁-C₆ alkyl,

20

W represents a single chemical bond between the two rings, a CH₂, O, S group or a NR¹⁴ radical,


wherein R¹⁴ is hydrogen or a linear or branched C₁-C₆ alkyl,

m is 0, 1, 2, 3 or 4 and

5

m1 is 1 or 2.

8. A sulfonamide compound of general formula (Ib),



10

wherein

R¹ represents a -NR⁸R⁹ radical,

15

R², R³, R⁵, R⁶ and R⁷, identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl or an optionally at least mono-substituted heteroaryl radical,

20

R⁴ is hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

25

R⁸ and R⁹, identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted C₁₋₄ aliphatic radical,

5

A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

10

and

n is 0, 1, 2, 3 or 4;

15

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof.

20

9. A compound according to claim 8, characterized in that R², R³, R⁵, R⁶ and R⁷, identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C₁-C₆ alkyl radical, a linear or branched, optionally at least mono-substituted C₂-C₆ alkenyl radical, or a linear or branched, optionally at least mono-substituted C₂-C₆ alkynyl radical,

25


preferably R², R³, R⁵, R⁶ and R⁷, identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C₁-C₆ alkyl radical,

30

more preferably R², R³, R⁵, R⁶ and R⁷ each represent hydrogen.

10. A compound according to claim 8 or 9, characterized in that R⁴ represents hydrogen, a linear or branched, optionally at least mono-substituted C₁-C₆ alkyl radical, a linear or branched, optionally at least mono-substituted C₂-C₆ alkenyl radical, a linear or branched, optionally at least mono-substituted C₂-C₆ alkynyl radical,
5 preferably that R⁴ represents hydrogen or a linear or branched, optionally at least substituted C₁-C₆ alkyl radical,
- 10 more preferably R⁴ represents hydrogen or a C₁-C₂ alkyl radical.
11. A compound according to one or more of claims 8 to 10, characterized in that R⁸ and R⁹, identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C₁-C₄ alkyl radical,
15 preferably R⁸ and R⁹ represent hydrogen or a C₁-C₂ alkyl radical, with the proviso that R⁸ and R⁹ are not hydrogen at the same time.
12. A compound according to one or more of claims 8 to 11, characterized in
20 that A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered, which may be bonded via an optionally at least mono-substituted C₁-C₆ alkylene group, an optionally at least mono-substituted C₂-C₆ alkenylene group or an optionally at least mono-substituted C₂-C₆ alkynylene group and/or wherein the ring(s) may contain at least one
25 heteroatom as a ring member,
preferably A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one
30 heteroatom,

or a radical chosen from the group consisting of



5 wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, linear or branched C₁-C₆ alkyl, linear or branched C₁-C₆ alkoxy, linear or branched C₁-C₆ alkylthio, a trifluoromethyl radical, a cyano radical and a -NR¹²R¹³ radical,

10 wherein R¹² and R¹³, identical or different, each represent hydrogen or linear or branched C₁-C₆ alkyl,

15 W represents a single chemical bond between the two rings, a CH₂, O, S group or a NR¹⁴ radical,

wherein R¹⁴ is hydrogen or a linear or branched C₁-C₆ alkyl,


20 m is 0, 1, 2, 3 or 4 and

m1 is 1 or 2.

13. A compound according to one or more of claims 8 to 12 selected from
5 the group consisting of

- [1] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide,
10 [2] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-naphthalene-2-sulfonamide,
[3] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-naphthalene-1-sulfonamide,
15 [4] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-4-phenylbenzenesulfonamide,
[5] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-2-(naphthalene-1-yl)-ethanesulfonamide,
20 [6] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-4-phenoxybenzenesulfonamide,
[7] N-[1-(2-dimethylaminoethyl)-1H-indole-4-yl]-3,5-dichlorobenzenesulfonamide and
25 [8] 6-chloro-N-[1-(2-dimethylaminoethyl)-1H-indol-4-yl]-imidazo[2,1-b]thiazole-5-sulfonamide
30 and their corresponding salts and solvates.


14. A process for obtaining a sulfonamide derivative of general formula (Ia) and/or (Ib), according to one or more of claims 1 - 13, characterized in that a compound of general formula (II), or one of its suitably protected derivatives,



(II)

5

wherein A has the meaning according to one or more of claims 1 - 13, and X is an acceptable leaving group, preferably a halogen atom, more preferably chlorine is reacted with at least one 4-aminoindole of general formula (III), or one of its suitably protected derivatives;



10

(III)

wherein R¹-R⁷ and n have the meaning according to one or more of claims 1 - 13 to obtain the corresponding sulfonamide and optionally, from the latter, the protective groups may be removed if necessary.

15. A process for obtaining a sulfonamide derivative of general formula (Ia) and/or (Ib), according to one or more of claims 1 - 13, wherein R¹-R³, R⁵-R⁷, n and A have the meaning according to one or more of claims 1 - 13, and R⁴ represents C₁-C₆ alkyl, characterized by reacting at least one compound of general formula (Ia) and/or at least one compound of general formula (Ib), wherein R¹-R³, R⁵-R⁷, n and A have the meaning according to one or more of claims 1 - 13, and R⁴ represents an hydrogen atom, with an alkyl halogenide or dialkyl sulfate.

20

16. A process for preparing the salts, preferably the physiologically acceptable salts of the compounds of general formula (Ia) and/or (Ib), according to one or more of claims 1 - 13, consisting of reacting at least one compound of the general formula (Ia) and/or at least one compound of the general formula (Ib) with a mineral acid or organic acid in a suitable solvent.
17. A medicament comprising least one compound according to one or more of claims 1 to 7 and optionally one or more pharmacologically acceptable excipients.
18. A medicament according to claim 17, for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and/or multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder),
30 preferably for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia,

anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome.

5

19. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for 5-HT₆ receptor regulation.
- 10 20. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of a disorder or disease related to food intake.
- 15 21. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the regulation of appetite.
22. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the maintenance, increase or reduction of body weight.
- 20 23. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of obesity.
- 25 24. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of bulimia.
- 30 25. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of anorexia.

26. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of cachexia.
- 5 27. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity.
- 10 28. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of gastrointestinal tract disorders.
- 15 29. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of irritable bowel syndrome.
- 20 30. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of anxiety.
- 25 31. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of depression.
- 30 32. The use of at least one compound according to one more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of bipolar disorders.
33. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of cognitive memory disorders.

34. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of senile dementia processes.
5
35. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of Alzheimer's Disease.
- 10 36. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of Parkinson's Disease.
- 15 37. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of Huntington's Disease.
- 20 38. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of dementias in which a cognitive deficit predominates.
- 25 39. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of Multiple Sclerosis.
40. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of psychosis.

41. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder).
- 5
42. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system.
- 10 43. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for the prophylaxis and/or treatment of schizophrenia.
- 15 44. The use of at least one compound according to one or more of claims 1 to 7 for the manufacture of a medicament for cognitive enhancement.
- 20 45. A medicament comprising at least one compound according to one or more of claims 8 to 13 and optionally one or more pharmacologically acceptable excipients.
- 25 46. A medicament according to claim 45 for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease,

Parkinson's disease, Huntington's disease and/or multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder),

5 preferably for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and
10 multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder).

- 15 47. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for 5-HT₆ receptor regulation.
48. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of a disorder or disease related to food intake.
- 20 49. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the regulation of appetite.
50. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the maintenance, increase
25 or reduction of body weight.
51. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of obesity.

52. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of bulimia.
- 5 53. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of anorexia.
- 10 54. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of cachexia.
- 15 55. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of type II diabetes (non-insulin-dependent diabetes mellitus), preferably type II diabetes caused by obesity.
- 20 56. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of gastrointestinal tract disorders.
- 25 57. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of irritable bowel syndrome.
58. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of anxiety.
- 30 59. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of depression.

60. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of bipolar disorders.
5
61. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of cognitive memory disorders.
- 10 62. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of senile dementia processes.
- 15 63. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of Alzheimer's Disease.
- 20 64. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of Parkinson's Disease.
- 25 65. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of Huntington's Disease.
66. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of Multiple Sclerosis.
- 30 67. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of dementias in which a cognitive deficit predominates.

68. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of psychosis.

5

69. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder).

10

70. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system.

15

71. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for the prophylaxis and/or treatment of schizophrenia.

20

72. The use of at least one compound according to one or more of claims 8 to 13 for the manufacture of a medicament for cognitive enhancement.